HSA approves new asthma indication for GSK's Trelegy Ellipta, the first once-daily single inhaler triple therapy approved for use in the treatment of both asthma and COPD in Singapore
- Written by PR Newswire
 |
SINGAPORE, April 5, 2024 /PRNewswire/ -- GSK Singapore announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled...
